Literature DB >> 15712019

[Prevalence and pharmacotherapy of diabetes mellitus in primary care].

H Lehnert1, H-U Wittchen, D Pittrow, P Bramlage, W Kirch, S Böhler, M Höfler, E Ritz.   

Abstract

BACKGROUND AND
OBJECTIVE: So far only incomplete epidemiological data on the management of diabetes mellitus have been available for the Federal Republic of Germany. It was the aim of this study to obtain such information from a representative cross-section of patients. PATIENTS AND METHODS: 43549 consecutive, unselected patients (52.6% females; mean age 64.9 +/- 11.7 years) of general practitioners and internists in private practice were included in this study which was based on data provided by the general practitioners or internists during September 2001. They recorded prevalence of diabetes, hypertension and 22 other diseases, and the patients' current treatment. Also recorded were associations of other patient-related variables (age, gender, associated or resulting diseases, hypertension, micro- and macrovascular complications, obesity), with medical practitioner-related variables (medical training, use of guidelines, regional factors) and with the frequency of antidiabetic treatment (total and differentiated by class of drug).
RESULTS: The prevalence of diabetes mellitus in this cohort was 15.6% (18.5% for males and 13.7% for females). 67.6% of the diabetics received antidiabetic medication. There was little difference, between the different age groups and between males and females, with regard to which of the various drugs were prescribed. Patients with macrovascular complications were more intensively treated with antidiabetics than those with exclusively microvascular ones. There was hardly any correlation between patterns of prescription and various practitioner characteristics (medical training, use of guidelines, regional factors).
CONCLUSION: There was little differentiation in the prescription of antidiabetic medication by general practitioners/internists among an unselected patient cohort.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15712019     DOI: 10.1055/s-2005-863050

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  7 in total

1.  The economic burden of diabetic retinopathy in Germany in 2002.

Authors:  Michael Happich; Ursula Reitberger; Lusine Breitscheidel; Michael Ulbig; Jessamy Watkins
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-04-04       Impact factor: 3.117

2.  [Medical decision making in symptoms of type 2 diabetes mellitus in general practice].

Authors:  W de Cruppé; O von dem Knesebeck; E Gerstenberger; C Link; L Marceau; J Siegrist; M Geraedts; J McKinlay
Journal:  Dtsch Med Wochenschr       Date:  2011-02-17       Impact factor: 0.628

3.  Antihypertensive effect of irbesartan and predictors of response in obesity-associated hypertension : a prospective, open-label study.

Authors:  Arya M Sharma; Peter Bramlage; Wilhelm Kirch
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 4.  Mobile applications for diabetics: a systematic review and expert-based usability evaluation considering the special requirements of diabetes patients age 50 years or older.

Authors:  Madlen Arnhold; Mandy Quade; Wilhelm Kirch
Journal:  J Med Internet Res       Date:  2014-04-09       Impact factor: 5.428

5.  Control of cardiovascular risk factors and its determinants in the general population- findings from the STAAB cohort study.

Authors:  Theresa Tiffe; Martin Wagner; Viktoria Rücker; Caroline Morbach; Götz Gelbrich; Stefan Störk; Peter U Heuschmann
Journal:  BMC Cardiovasc Disord       Date:  2017-11-02       Impact factor: 2.298

6.  Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study.

Authors:  Heike U Krämer; Elke Raum; Gernot Rüter; Ben Schöttker; Dietrich Rothenbacher; Thomas Rosemann; Joachim Szecsenyi; Hermann Brenner
Journal:  Cardiovasc Diabetol       Date:  2012-07-27       Impact factor: 9.951

7.  First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation.

Authors:  Walter Zidek; Joachim Schrader; Stephan Lüders; Stephan Matthaei; Christoph Hasslacher; Joachim Hoyer; Peter Bramlage; Claus-Dieter Sturm; W Dieter Paar
Journal:  Cardiovasc Diabetol       Date:  2008-07-24       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.